Tofogliflozin Reduces 24-h Ambulatory Blood Pressure in inpatients with Type 2 Diabetes and Hypertensio
Not Applicable
- Conditions
- Type 2 diabetes with hypertension
- Registration Number
- JPRN-UMIN000022580
- Lead Sponsor
- Dokkyo Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) Type 1 diabetes 2) Severe diabetic complications such as ketoacidosis 3) Severe renal dysfunction(estimated glomerular filtration rate [eGFR] < 30 mL/min/) 4) Pregnant or nursing women and those who might be pregnant 5) Chronic heart failure, 6) Haemodialysis, 7) A history of stroke and cardiovascular events, 8) Any patient whom the investigator judged to be inappropriate for this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 24h-blood pressure(systolic and diastolic) before and after the administration of 20mg tofogliflozin.
- Secondary Outcome Measures
Name Time Method Holter electrocardiograph,power spectrum analysis,NT-proBNP and D-ROMs before and after the administration of tofogliflozin.